[go: up one dir, main page]

MX2009007391A - Metodos para aumentar e inmovilizar células madre hematopoyéticas. - Google Patents

Metodos para aumentar e inmovilizar células madre hematopoyéticas.

Info

Publication number
MX2009007391A
MX2009007391A MX2009007391A MX2009007391A MX2009007391A MX 2009007391 A MX2009007391 A MX 2009007391A MX 2009007391 A MX2009007391 A MX 2009007391A MX 2009007391 A MX2009007391 A MX 2009007391A MX 2009007391 A MX2009007391 A MX 2009007391A
Authority
MX
Mexico
Prior art keywords
increasing
stem cells
hematopoietic stem
methods
mobilizing hematopoietic
Prior art date
Application number
MX2009007391A
Other languages
English (en)
Inventor
Alexander N Shakhov
Evguenia Strom
Original Assignee
Cleveland Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc filed Critical Cleveland Biolabs Inc
Publication of MX2009007391A publication Critical patent/MX2009007391A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un método para aumentar el número de células madre hematopoyéticas, en la médula ósea, aumentar la movilidad de estas células para migrar de la médula ósea al flujo sanguíneo y a otras partes, y aumentar el número de células madre hematopoyéticas diferenciadas en el flujo sanguíneo.
MX2009007391A 2007-01-09 2008-01-09 Metodos para aumentar e inmovilizar células madre hematopoyéticas. MX2009007391A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88416207P 2007-01-09 2007-01-09
US88989307P 2007-02-14 2007-02-14
US93856407P 2007-05-17 2007-05-17
US1324307P 2007-12-12 2007-12-12
PCT/US2008/050644 WO2008086426A2 (en) 2007-01-09 2008-01-09 Methods for increasing and mobilizing hematopoietic stem cells

Publications (1)

Publication Number Publication Date
MX2009007391A true MX2009007391A (es) 2009-08-13

Family

ID=39609361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007391A MX2009007391A (es) 2007-01-09 2008-01-09 Metodos para aumentar e inmovilizar células madre hematopoyéticas.

Country Status (14)

Country Link
US (3) US20100055077A1 (es)
EP (1) EP2115124B1 (es)
JP (1) JP5389666B2 (es)
KR (1) KR101493474B1 (es)
CN (1) CN101631850B (es)
BR (1) BRPI0806557A2 (es)
CA (1) CA2675032A1 (es)
EA (1) EA018983B1 (es)
IL (1) IL199766A (es)
MX (1) MX2009007391A (es)
NZ (2) NZ603805A (es)
SG (1) SG177959A1 (es)
WO (1) WO2008086426A2 (es)
ZA (1) ZA200905378B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904084B1 (en) 2005-06-13 2013-04-24 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
EP2493295A4 (en) * 2009-10-28 2013-05-08 Ford Henry Health System METHOD FOR MINIMIZING LESIONS DUE TO RADIATION EXPOSURE
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
WO2012037283A2 (en) * 2010-09-14 2012-03-22 Mount Sinai School Of Medicine Admimistration of sns neuroprotective agents to promote hematopoietic regeration
MX352373B (es) 2011-03-31 2017-11-22 Adc Therapeutics Sa Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
IN2014CN04690A (es) 2012-01-09 2015-09-18 Alethia Biotherapeutics Inc
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
AU2013248972A1 (en) 2012-04-20 2014-11-13 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
JP2016518415A (ja) * 2013-10-21 2016-06-23 アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー 加齢と疾患免疫機能障害と細胞老化とをリンパ球系幹細胞で修復する方法、及び治療使用のためのそれらの再適用する方法
CN104744563B (zh) * 2013-12-27 2019-02-26 中国人民解放军军事医学科学院毒物药物研究所 端基具有亲脂性结构的线性脂肽、其制备方法及用途
WO2016073733A1 (en) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Methods of treating cancer using lipopeptides
WO2020047236A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
DE19822820A1 (de) * 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
EP1904084B1 (en) * 2005-06-13 2013-04-24 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
BRPI0715393A2 (pt) * 2006-08-07 2013-06-25 Genzyme Corp terapia de combinaÇço

Also Published As

Publication number Publication date
AU2008204836A1 (en) 2008-07-17
JP5389666B2 (ja) 2014-01-15
WO2008086426A2 (en) 2008-07-17
US20100055077A1 (en) 2010-03-04
NZ578928A (en) 2013-03-28
BRPI0806557A2 (pt) 2014-04-15
NZ603805A (en) 2014-03-28
US20140045747A1 (en) 2014-02-13
IL199766A (en) 2015-01-29
EA018983B1 (ru) 2013-12-30
WO2008086426A3 (en) 2008-12-18
JP2010515748A (ja) 2010-05-13
CN101631850A (zh) 2010-01-20
EP2115124B1 (en) 2016-03-16
ZA200905378B (en) 2010-05-26
CA2675032A1 (en) 2008-07-17
KR20090108703A (ko) 2009-10-16
EP2115124A4 (en) 2012-05-30
EA200900806A1 (ru) 2010-08-30
WO2008086426A8 (en) 2009-07-30
EP2115124A2 (en) 2009-11-11
HK1134835A1 (en) 2010-05-14
US20150174195A1 (en) 2015-06-25
KR101493474B1 (ko) 2015-02-16
SG177959A1 (en) 2012-02-28
CN101631850B (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
MX2009007391A (es) Metodos para aumentar e inmovilizar células madre hematopoyéticas.
IL189882A0 (en) Method of deriving mesenchymal stem cells
EP2231992A4 (en) METHOD AND DEVICE FOR IMPROVING THE DESIGN, PRODUCTION, PERFORMANCE AND / OR USE OF DRILLING TOOLS
MY159971A (en) Multipotent/pluripotent cells and methods
MX2013014307A (es) Metodo de tratamiento de celulas madre mesenquinales y su uso en el tratamiento de enfermedades asociadas a estres oxidativo.
IL216902A0 (en) Methods for culturing stem and progentitor cells
EP2594636A4 (en) CULTURE MEDIUM COMPOSITION FOR CULTURING MESENCHYMAL STEM CELLS FROM AMNIOTIC MEMBRANE, AND METHOD FOR CULTURING THE SAME USING THE SAME
EP1974022A4 (en) MASS PRODUCTION PROCESS FOR GROWTH FACTOR USING FAT-WEB-GENERATING ADULTS STEM CELLS
ZA201202685B (en) Methods of preparing mesenchymal stem cells,compositions and kit thereof
PL2495302T3 (pl) Urządzenie biologiczne do ekstrakcji krwiotwórczych komórek macierzystych i mezenchymalnych komórek macierzystych z krwi obwodowej
WO2013070881A8 (en) Method for elimination of space through tissue approximation
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
EP2438589A4 (en) SYSTEM AND METHOD FOR RECEIVING, ANALYZING AND EDITING AUDIO FOR GENERATING MUSIC COMPOSITIONS
WO2010129441A3 (en) Method for separating stem cells from their more differentiated progeny using microfluidic devices
EP2407245A4 (en) CENTRIFUGAL SEPARATION KIT, AND CENTRIFUGAL SEPARATION METHOD USING THE SAME
GB0710095D0 (en) Culture method of stem cell
PL2410046T3 (pl) Sposób izolowania pluripotencjalnych komórek macierzystych pochodzących z krwi pępowinowej wykazujących ekspresję ZNF281
EP2119768A4 (en) METHOD FOR MANUFACTURING MESENCHYMAL CELL, METHOD FOR MANUFACTURING TOOTH AND MESENCHYMAL CELL FOR TOOTH FORMATION
EP2218792A4 (en) PROCESS FOR PREPARATION OF A KOTPROBE, SOLUTION FOR PREPARATION OF A KOTPROBE AND KOTSAMMELKIT
PL2226129T3 (pl) Sposoby formowania odpornych na erozję kompozytów, sposoby ich wykorzystywania, oraz ziemne narzędzia wiertnicze wykorzystujące te kompozyty w wewnętrznych kanałach
EP2420569A4 (en) METHOD FOR THE CULTURE OF BONE MARROW STROMAL CELLS AND MESENCHYMAL STEM CELLS, AND METHOD FOR THE PRODUCTION OF GRAFT CELLS FOR THE TREATMENT OF CENTRAL NEUROLOGICAL DISEASE
ZA200904706B (en) Process to produce biomass and proteins by microalgae
IL194175A0 (en) Methods to maintain, improve and restore the cartilage phenotype of chondrocytes
WO2010022194A3 (en) Compositions and methods for generation of pluripotent stem cells
ATE480615T1 (de) Verfahren zur proliferation von stammzellen

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration